Since recurrences after TKI cessation are always ABL-TKI sensitive [20–22], the underlying nature of CML stem cell persistence is evidently BCR-ABL-independent. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.